Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 491.73M | 460.48M | 434.48M | 411.35M | 398.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 491.73M | 460.48M | 434.48M | 411.35M | 398.20M |
| Cost of Revenue | 70.62M | -17.84M | 57.43M | 55.04M | 53.45M |
| Gross Profit | 421.11M | 478.32M | 377.04M | 356.31M | 344.76M |
| SG&A Expenses | 177.74M | 175.58M | 163.26M | 150.93M | 133.71M |
| Depreciation & Amortization | 37.38M | 37.09M | 36.23M | 35.38M | 32.57M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 296.61M | 286.51M | 348.60M | 333.02M | 311.39M |
| Operating Income | 195.12M | 173.97M | 85.88M | 78.33M | 86.81M |
| Income Before Tax | 216.26M | 188.79M | 93.56M | 86.29M | 94.51M |
| Income Tax Expenses | 52.37M | 45.99M | 25.41M | 21.17M | 23.10M |
| Earnings from Continuing Operations | 163.89 | 142.80 | 68.15 | 65.12 | 71.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 163.89M | 142.80M | 68.15M | 65.12M | 71.41M |
| EBIT | 195.12M | 173.97M | 85.88M | 78.33M | 86.81M |
| EBITDA | 232.90M | 211.43M | 122.45M | 114.04M | 119.69M |
| EPS Basic | 1.38 | 1.24 | 0.58 | 0.59 | 0.67 |
| Normalized Basic EPS | 1.11 | 1.01 | 0.50 | 0.47 | 0.54 |
| EPS Diluted | 1.31 | 1.18 | 0.54 | 0.54 | 0.61 |
| Normalized Diluted EPS | 1.05 | 0.95 | 0.46 | 0.43 | 0.49 |
| Average Basic Shares Outstanding | 473.81M | 460.63M | 448.27M | 436.35M | 425.10M |
| Average Diluted Shares Outstanding | 499.75M | 487.22M | 468.38M | 457.40M | 447.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
